Literature DB >> 31576300

Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy.

Makito Miyake1, Takuya Owari1, Kiyohide Fujimoto1.   

Abstract

Entities:  

Year:  2019        PMID: 31576300      PMCID: PMC6685894          DOI: 10.21037/atm.2019.04.52

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  25 in total

1.  The skeletal metastatic complications of renal cell carcinoma.

Authors:  J Zekri; N Ahmed; R E Coleman; B W Hancock
Journal:  Int J Oncol       Date:  2001-08       Impact factor: 5.650

Review 2.  Monitoring of bone metastases.

Authors:  R E Coleman
Journal:  Eur J Cancer       Date:  1998-02       Impact factor: 9.162

3.  Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.

Authors:  F Ruatta; L Derosa; B Escudier; E Colomba; A Guida; G Baciarello; Y Loriot; K Fizazi; L Albiges
Journal:  Eur J Cancer       Date:  2018-12-11       Impact factor: 9.162

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma.

Authors:  Grant K Hunter; Ehsan H Balagamwala; Shlomo A Koyfman; Trevor Bledsoe; Lawrence J Sheplan; Chandana A Reddy; Samuel T Chao; Toufik Djemil; Lilyana Angelov; Gregory M M Videtic
Journal:  Pract Radiat Oncol       Date:  2012-02-15

6.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Authors:  Reuben J Broom; Victoria Hinder; Katrina Sharples; Janie Proctor; Steven Duffey; Stephanie Pollard; Peter C C Fong; Garry Forgeson; Dean L Harris; Michael B Jameson; Anne O'Donnell; Richard T North; Sanjeev Deva; Fritha J Hanning; Andrew Grey; Michael P N Findlay
Journal:  Clin Genitourin Cancer       Date:  2014-07-15       Impact factor: 2.872

8.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Authors:  David Henry; Saroj Vadhan-Raj; Vera Hirsh; Roger von Moos; Vania Hungria; Luis Costa; Penella J Woll; Giorgio Scagliotti; Geoffrey Smith; Amy Feng; Susie Jun; Roger Dansey; Howard Yeh
Journal:  Support Care Cancer       Date:  2013-10-26       Impact factor: 3.603

9.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

10.  Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

Authors:  Daniele Santini; Giuseppe Procopio; Camillo Porta; Toni Ibrahim; Sandro Barni; Calogero Mazzara; Andrea Fontana; Alfredo Berruti; Rossana Berardi; Bruno Vincenzi; Cinzia Ortega; Davide Ottaviani; Giacomo Carteni; Gaetano Lanzetta; Vladimir Virzì; Matteo Santoni; Nicola Silvestris; Maria Antonietta Satolli; Elena Collovà; Antonio Russo; Giuseppe Badalamenti; Stefano Luzi Fedeli; Francesca Maria Tanca; Vincenzo Adamo; Evaristo Maiello; Roberto Sabbatini; Alessandra Felici; Saverio Cinieri; Giuseppe Tonini; Sergio Bracarda
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

View more
  1 in total

1.  External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy.

Authors:  Takuya Owari; Makito Miyake; Yasushi Nakai; Nobumichi Tanaka; Yoshitaka Itami; Shuya Hirao; Hitoshi Momose; Yoshinori Nakagawa; Kouta Iida; Fumisato Maesaka; Takuto Shimizu; Yusuke Iemura; Yoshihiro Matsumoto; Masaomi Kuwada; Takeshi Otani; Kenji Otsuka; Eijiro Okajima; Yukinari Hosokawa; Ryosuke Okamura; Kiyohide Fujimoto
Journal:  J Bone Oncol       Date:  2020-12-13       Impact factor: 4.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.